Oral Oncolytics Series: Leukemia, 2014 - 2024

News provided by

Jun 04, 2014, 12:41 ET

NEW YORK, June 4, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Oral Oncolytics Series: Leukemia, 2014 - 2024

http://www.reportlinker.com/p02132245/Oral-Oncolytics-Series-Leukemia-2014---2024.html

INTRODUCTION

Targeted therapeutics is fast emerging as the key focus area in biopharmaceutical industry. Oral targeted therapeutics has attracted many drug developers due to the ease of administration it offers to patients (especially pediatric and geriatric patients). In the case of leukemia, current marketed oral drugs include Gleevec, Tasigna, Sprycel, Bosulif, Imbruvica and Iclusig.

The high price of these drugs still remains a major constraint to the market growth. Further, as leukemia accounts for about 3% of all cancer cases per year, most of the companies are targeting other cancer indications offering a wider market prospective. The oral targeted drugs market is expected to be driven by new generation and new class of inhibitors. Several pharmaceutical companies, both big and small, are looking to capture a share of the leukemia market, where orally delivered drugs are well accepted.

Despite the impending patent expiry of some drugs (especially Gleevec), the market is set to rise after a likely dip in growth rate in the short-term. There are specific opportunities which remain to be tapped in the mid-long term; emerging drug therapies such as third generation tyrosine kinase inhibitors (TKIs), multi kinase inhibitors, FLT3 inhibitors, AKT kinase inhibitors and BTK inhibitors are likely to sustain the interest of drug makers.

SCOPE OF THE REPORT

The 'Oral Oncolytics Series: Leukemia, 2014 - 2024' report provides an extensive study of the market of oral targeted leukemia drugs, specifically focusing on currently commercialized drugs, those under development and the likely future market evolution. Targeted therapeutics have tremendous potential and the market is expected to grow steadily over the coming few years. The focus of our report is on drugs which target a specific marker / antigen on leukemia cells and are delivered through mouth. The report covers various aspects such as regulatory approvals, treatment cost, historical sales, product pipeline and industry research programs.

With the upcoming patent expiry of some well-known drugs, we have looked at how the market landscape is likely to change in the coming years. In fact, one of the key objectives of this report is to understand the current and future state of the oral targeted leukemia drugs. This is done by analyzing the following:
- Marketed oral targeted leukemia drugs
- Products in pipeline
- Competing technologies and innovations
- Growing target patient pool

The base year for the report is 2013. The report provides short-mid term and long term forecasts for the period 2014 - 2024. This forecast is supported by detailed research and analysis of drugs (both marketed / pipeline) which we believe will have a far-reaching impact on the market. Owing to the uncertainties associated with drug development and customer adoption trends, we have presented three different market scenarios for each of the drugs studied in this exercise:
- Conservative Scenario: This represents our most pessimistic view of the success / adoption of each individual drug.
- Base Scenario: This represents the most-likely success / adoption of respective drugs.
- Aggressive Scenario: This is the bullish scenario wherein we have been aggressive in terms of the penetration rates of respective drugs and the likely market size.

EXAMPLE HIGHLIGHTS

1. The market for oral targeted leukemia therapeutics was valued at USD 7,388 million in 2013; CML drugs currently dominate the market.
2. US, with a 40.6% share, is currently the biggest market. According to the Leukemia & Lymphoma Society, there are an estimated 310,046 people living with, or in remission from, leukemia in the US
3. Gleevec, the market leader, has been quite popular amongst patient population. However, its nearing patent expiry (2014, 2015, 2016 in Japan, the US and Europe respectively) will open the space for low cost generics
4. There are several upcoming drugs, with a sizeable number in phase II and phase III clinical trials. Opportunities for drug developers exist in all forms of leukemia.
5. AML has the most extensive pipeline; in addition to tyrosine kinases, hedgehog, JAK, PI3K inhibitors, drug developers are also exploring the use of epigenetic agents such as histone deacetylases (HDAC) and nuclear export inhibitors such as XPO1 inhibitor.
6. Novartis is the most active company in this market, with two marketed drugs and another eight in clinical trials. Specifically, within AML (which currently has no marketed oral drug), Novartis' Midostaurin is expected to have the first mover advantage.

RESEARCH METHODOLOGY

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Other analysts' opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of oral targeted leukemia market.

Chapter 3 provides a general introduction to leukemia. We have discussed, in detail, about types of leukemia, common signs and symptoms, its occurrence / prevalence and the current treatment regimes.
Chapter 4 provides an overview of the global leukemia therapeutics market, specifically the targeted therapeutics which includes small molecule inhibitors and monoclonal antibodies. The market has been analyzed on the basis of the type of leukemia, drug classes, and leading drugs in each segment.

Chapter 5 analyzes the current and future state of the worldwide market of oral targeted leukemia drugs. This chapter includes detailed profiles of all the marketed drugs and the drugs in phase III clinical trials. We have presented our estimates of the overall market value of oral targeted leukemia drugs till 2024.

Chapter 6 offers a region wise market analysis of the oral targeted leukemia drugs. This chapter covers the geographical availability and reimbursement policies of the oral targeted leukemia drugs. The major regional markets considered are the US, Europe and Japan.

Chapter 7 provides our analysis of the strengths, weaknesses, opportunities and threats impacting the oral targeted leukemia market, capturing key elements likely to influence future growth.

Chapter 8 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in earlier chapters.

Chapters 9 and 10 are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.

TABLE OF CONTENTS

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. Executive Summary

3. Introduction
3.1. Leukemia
3.2. Types Of Leukemia
3.3. Common Signs And Symptoms
3.4. Incidence And Prevalence
3.5. Current Treatment Regimes

4. Market Overview
4.1. Chapter Overview
4.2. Scope
4.3. Targeted Leukemia Therapeutics Market, 2013
4.3.1. Approved Targeted Leukemia Therapeutics, 2013
4.3.2. Within Leukemia, CML Drugs Dominate the Market
4.3.3. Four Leading Drugs Captured 98% of the Market in 2013
4.4. Oral Targeted Leukemia Therapeutics Market, 2013
4.5. Pipeline Analysis: By Specific Leukemia Sub-Types
4.5.1. Chronic Myeloid Leukemia (CML)
4.5.1.1. A Mature Market; Impending Threat of Patent Expiry
4.5.1.2. Development of Next Generation TKIs
4.5.1.3. Unravelling the Potential of Inhibitors Other Than Tyrosine Kinases
4.5.2. Chronic Lymphocytic Leukemia
4.5.2.1. Gazyva: Successor for Rituxan
4.5.2.2. Rich Pipeline Mainly Focusing on Relapsed / Refractory Population
4.5.3. Acute Myeloid Leukemia
4.5.3.1. A High Opportunity Area
4.5.3.2. Epigenetic Agents and Nuclear Export Inhibitors
4.5.4. Acute Lymphocytic / Lymphoblastic Leukemia (ALL)
4.5.4.1. Most Common Cancer in Children
4.5.4.2. Limited Molecules in Pipeline
4.6. Other Oral Targeted Drugs for Haematological Malignancies

5. Oral Targeted Leukemia Drugs: Current Market and Forecast
5.1. Chapter Overview
5.1.1. Scope and Limitations
5.1.2. Market Forecast: Assumptions and Methodology
5.2. Overall Market Size and Forecast
5.2.1. Overall Oral Targeted Leukemia Drugs Market Forecast

5.3. Imatinib (Novartis Pharmaceuticals)
5.3.1. History of Development
5.3.2. Approval History
5.3.3. Mechanism of Action
5.3.4. Pricing and Reimbursement
5.3.5. Historical Sales
5.3.6. Launch of Generics in the Market
5.3.7. Withdrawal of Development in PAH
5.3.8. Gleevec Sales Forecast, Short-Mid Term (2014-2018)
5.3.9. Gleevec Sales Forecast, Long Term (2018-2024)

5.4. Nilotinib (Novartis Pharmaceuticals)
5.4.1. Approval History
5.4.2. Mechanism of Action
5.4.3. Tasigna and Gleevec: Novartis' BCR/ABL Franchise
5.4.3.1. Moving Gleevec Patients to Tasigna before Patent Expiry
5.4.4. Treatment Cost
5.4.5. Historical Sales
5.4.6. Active Clinical Trials
5.4.7. Tasigna Sales Forecast, Short-Mid Term (2014-2018)
5.4.8. Tasigna Sales Forecast, Long Term (2018-2024)

5.5. Dasatinib (Bristol-Myers Squibb)
5.5.1. Orphan Drug Designations
5.5.2. Approval History
5.5.3. Mechanism of Action
5.5.4. Pricing and Reimbursement
5.5.5. Historical Sales
5.5.6. Active Clinical Trials
5.5.7. Patent Expiry and Generics
5.5.8. Sprycel Sales Forecast, Short-Mid Term (2014-2018)
5.5.9. Sprycel Sales Forecast, Long Term (2018-2024)

5.6. Bosutinib (Pfizer Inc.)
5.6.1. Approval History
5.6.2. Mechanism of Action
5.6.3. Pricing and Reimbursement
5.6.4. Historical Sales
5.6.5. Ongoing Clinical Trials
5.6.5.1. Partnership With Avillion for First-Line Treatment
5.6.6. Manufacturing
5.6.7. Bosutinib Sales Forecast, Short-Mid Term (2014-2018)
5.6.8. Bosutinib Sales Forecast, Long Term (2018-2024)

5.7. Ponatinib (ARIAD Pharmaceuticals, Inc.)
5.7.1. Approval and Launch History
5.7.2. Mechanism of Action
5.7.3. Setback and Re-launch in the US
5.7.4. Pricing and Reimbursement
5.7.5. Historical Sales
5.7.6. Ongoing Clinical Trials
5.7.7. Manufacturing
5.7.8. Iclusig Sales Forecast, Short-Mid Term (2014-2018)
5.7.9. Iclusig Sales Forecast, Long Term (2018-2024)

5.8. Ibrutinib (Pharmacyclics Inc./ Janssen Pharmaceuticals)
5.8.1. Historical Development
5.8.2. Breakthrough Therapy Designation
5.8.3. Mechanism of Action
5.8.4. Pricing and Reimbursement
5.8.5. Historical Sales
5.8.6. Market Expansion Strategies
5.8.7. Manufacturing of Ibrutinib
5.8.8. Ibrutinib Sales Forecast, Short-Mid Term (2014-2018)
5.8.9. Ibrutinib Sales Forecast, Long Term (2018-2024)

5.9. Idelalisib (Gilead Sciences, Inc.)
5.9.1. History of Development
5.9.2. Mechanism of Action
5.9.3. Another First-in-Class Inhibitor for CLL
5.9.4. Early Termination of Study GS-US-312-0116
5.9.5. Ongoing Clinical Trials
5.9.6. Idealisib Sales Forecast, Short-Mid Term (2014-2018)
5.9.7. Idealisib Sales Forecast, long term (2018-2024)

5.10. Midostaurin (Novartis Pharmaceuticals)
5.10.1. Orphan Drug Designations
5.10.2. Mechanism of Action
5.10.3. First Mover Advantage in the AML Market?
5.10.4. Screening for FLT3 Mutation
5.10.5. Active Clinical Trials
5.10.6. Midostaurin Sales Forecast, Short-Mid Term (2016-2018)
5.10.7. Midostaurin Sales Forecast, Long Term (2018-2024)

5.11. ABT-199 / GDC-0199 (Abbott / Roche)
5.11.1. Mechanism of Action
5.11.2. Screening for a Biomarker
5.11.3. A Temporary Clinical Hold
5.11.4. Active Clinical Trials
5.11.5. ABT-199 Sales Forecast, Long Term (2019-2024)

5.12. IPI – 145 (Infinity Pharmaceuticals / Millennium)
5.12.1. History of Development
5.12.2. Orphan Drug Designation
5.12.3. Mechanism of Action
5.12.4. Impressive Phase I Results Led to Phase III Trials
5.12.5. Active Clinical Trials
5.12.6. IPI-145 Sales Forecast, Long Term (2019-2024)

6. Regional Analysis of Oral Targeted Therapeutics Market
6.1. Overview
6.2. US is the Largest Market For Targeted Oral Leukemia Drugs
6.2.1. Epidemiology of Leukemia in the US
6.2.2. Availability and Reimbursement
6.3. Japan
6.3.1. Epidemiology of Leukemia in Japan
6.3.2. Availability and Reimbursement
6.4. Europe
6.4.1. Epidemiology of Leukemia in Europe
6.4.2. France
6.4.3. Germany
6.4.4. United Kingdom

7. SWOT Analysis
7.1. Overview
7.2. Strengths
7.2.1. Ease of Administration
7.2.2. Positive Reimbursement Status in Major Developed Countries
7.3. Weaknesses
7.3.1. Small Patient Pool
7.3.2. High Annual Treatment Cost
7.4. Opportunities
7.4.1. Development of next generation TKIs
7.4.2. Limited Treatment Options for Pediatric Patients at Present
7.5. Threats
7.5.1. Development of Vaccines
7.5.2. Competition from Monoclonal Antibody Therapeutics

8. Conclusion
8.1. Leukemia: A Rare Disease in Adults but Most Common Cancer in Children
8.2. Six Drugs for Leukemia, None for AML Group of Patients
8.3. High Annual Treatment Cost: A Concern, Reimbursement Schemes to Relief
8.4. Despite Impending Patent Expiries, Market Set to Rise Further
8.5. Concluding Remarks

9. Appendix 1: List of Companies and Organizations

10. Appendix 2: Tabulated Data

LIST OF FIGURES

Figure 3.1 Leukemia: Incidence Rate in the US (2013)
Figure 3.2 Leukemia: Incidence Rate in the US by Age Group (2006 – 2010)
Figure 4.1 Targeted Leukemia Drugs Market, 2013 – Split by Indication (USD Million)
Figure 4.2 Targeted Leukemia Drugs Market, 2013 – Split by Leading Drugs (USD Million)
Figure 4.3 Oral Targeted Leukemia Drugs Market, 2013 (USD Million)
Figure 4.4 Targeted CML Therapeutics Market, 2013 (USD Million) – Split by Leading Drugs
Figure 4.5 Oral Targeted CML Drugs, 2014 – Split by Phase of Development
Figure 4.6 Targeted CLL Therapeutics Market, 2013 – Split by Leading Drugs (USD Million)
Figure 4.7 Oral Targeted CLL Drugs, 2014 – Split by Phase of Development
Figure 4.8 Oral Targeted AML Drugs, 2014 – Split by Phase of Development
Figure 4.9 Targeted ALL Therapeutics Market, 2013 – Split by Leading Drugs
Figure 4.10 Oral Targeted ALL Drugs, 2014 – Split by Phase of Development
Figure 5.1 Overall Oral Targeted Leukemia Drugs Market Forecast: Base Scenario (USD Million)
Figure 5.2 Gleevec/Glivec Sales, 2005-2013 (USD Million)
Figure 5.3 Gleevec/Glivec Sales by Region, 2013 (%)
Figure 5.4 Gleevec Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Figure 5.5 Gleevec Sales Forecast, Long Term: Base Scenario (USD Million)
Figure 5.6 Novartis BCR/ABL Franchise Sales, 2013 (USD Million)
Figure 5.7 Tasigna Sales, 2008-2013 (USD Million)

Figure 5.8 Tasigna Sales by Region, 2013 (%)
Figure 5.9 Tasigna Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Figure 5.10 Tasigna Sales Forecast, Long Term: Base Scenario (USD Million)
Figure 5.11 Sprycel Sales, 2006-2013 (USD Million)
Figure 5.12 Sprycel Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Figure 5.13 Sprycel Sales Forecast, Long Term: Base Scenario (USD Million)
Figure 5.14 Bosutinib Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Figure 5.15 Bosutinib Sales Forecast, Long Term: Base Scenario (USD Million)
Figure 5.16 Iclusig Sales, 2013 (USD Million)
Figure 5.17 Iclusig Sales Distribution by Region, Q4 2013 (USD Million)
Figure 5.18 Iclusig Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Figure 5.19 Iclusig Sales Forecast, Long Term: Base Scenario (USD Million)
Figure 5.20 Ibrutinib Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Figure 5.21 Ibrutinib Sales Forecast, Long Term: Base Scenario (USD Million)
Figure 5.22 Idealisib Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Figure 5.23 Idealisib Sales Forecast, Long Term: Base Scenario (USD Million)
Figure 5.24 FLT3 Mutation in Acute Myeloid Leukemia Patients (%)
Figure 5.25 Midostaurin Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Figure 5.26 Midostaurin Sales Forecast, Long Term: Base Scenario (USD Million)
Figure 5.27 ABT-199 Sales Forecast, Long Term: Base Scenario (USD Million)
Figure 5.28 IPI-145 Sales Forecast, Long Term: Base Scenario (USD Million)
Figure 6.1 Oral Targeted Leukemia Drugs Market – Split by Regions, 2013 (%)
Figure 6.2 Prevalence of Leukemia in the US, 2013 (%)
Figure 6.3 Incidence of Types of Leukemia in the US, 2013 (%)
Figure 6.4 Oral Targeted Leukemia Drugs Market in the US, 2013 – Split by Drugs (USD Million)
Figure 6.5 Incidence of Leukemia in Japan, 2012
Figure 6.6 Leukemia Incidence: Major EU Countries, 2012
Figure 8.1 Oral Targeted Leukemia Drugs Market Forecast (USD Million): Comparative Scenarios

LIST OF TABLES

Table 4.1 List of Approved Targeted Drugs for ALL, 2013
Table 4.2 List of Approved Targeted Drugs for CLL, 2013
Table 4.3 List of Approved Targeted Drugs for CML, 2013
Table 4.4 Target Kinases for Approved Small Molecule Inhibitors
Table 4.5 Comparison of the Marketed Targeted Inhibitors for CML
Table 4.6 CML Pipeline: Oral Targeted Drugs, 2014
Table 4.7 Comparison of the Marketed Targeted Inhibitors for CLL
Table 4.8 Rituximab Biosimilars Under Development, 2014
Table 4.9 CLL Pipeline: Oral Targeted Drugs, 2014
Table 4.10 AML Pipeline: Oral Targeted Drugs, 2014
Table 4.11 Comparison of the Marketed Targeted Inhibitors for ALL
Table 4.12 ALL Pipeline: Oral Targeted Drugs, 2014
Table 4.13 Some More Oral Targeted Drugs for Leukemia, 2014
Table 5.1 Oral Targeted Leukemia Drugs (Phase III and Higher): Current Development Phase and Expected Launch Year
Table 5.2 Gleevec: Marketing Approvals
Table 5.3 Gleevec: Dosage Regime
Table 5.4 Tasigna: Orphan Drug Designation
Table 5.5 Tasigna: Marketing Approvals
Table 5.6 Tasigna: Treatment Duration and Cost
Table 5.7 Tasigna: Clinical Trials and Development Status
Table 5.8 Dasatinib: Orphan Drug Designation History
Table 5.9 Sprycel: Approval History
Table 5.10 Sprycel: Course and Treatment Cost
Table 5.11 Sprycel: Clinical Trials and Development Status
Table 5.12 Bosulif: Treatment Duration and Cost
Table 5.13 Bosulif: Clinical Trials and Development Status
Table 5.14 Ponatinib: Approval History
Table 5.15 Iclusig: Treatment Tenure

Table 5.16 Iclusig: Clinical Trials and Development Status
Table 5.17 Ibrutinib: Orphan Drug Designations
Table 5.18 Ibrutinib: Ongoing Clinical Trials
Table 5.19 Idelalisib: Clinical Trials and Development Status
Table 5.20 Midostaurin: Orphan Drug Designations
Table 5.21 Midostaurin: Clinical Trials and Development Status
Table 5.22 ABT-199: Clinical Trials and Development Status
Table 5.23 IPI - 145: Clinical Trials and Development Status
Table 6.1 Marketed Oral Targeted Drugs in Major Markets
Table 8.1 SWOT analysis of Oral Targeted Therapeutics for Leukemia
Table 10.1 Targeted Leukemia Drugs Market, 2013 – Split by Indication (USD Million)
Table 10.2 Targeted Leukemia Drugs Market, 2013 – Split by Leading Drugs (USD Million)
Table 10.3 Oral Targeted Leukemia Drugs Market, 2013 (USD Million)
Table 10.4 Targeted CML Therapeutics Market, 2013 (USD Million) – Split by Leading Drugs
Table 10.5 Targeted CLL Therapeutics Market, 2013 – Split by Leading Drugs (USD Million)
Table 10.6 Targeted ALL Therapeutics Market, 2013 – Split by Leading Drugs
Table 10.7 Overall Oral Targeted Leukemia Drugs Market Forecast, Short-Mid Term: Base Scenario (USD Million)
Table 10.8 Overall Oral Targeted Leukemia Drugs Market Forecast, Short-Mid Term: Conservative Scenario (USD Million)
Table 10.9 Overall Oral Targeted Leukemia Drugs Market Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
Table 10.10 Overall Oral Targeted Leukemia Drugs Market Forecast, Long Term: Base Scenario (USD Million)
Table 10.11 Overall Oral Targeted Leukemia Drugs Market Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.12 Overall Oral Targeted Leukemia Drugs Market Forecast, Long Term: Optimistic Scenario (USD Million)

Table 10.13 Gleevec Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Table 10.14 Gleevec Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
Table 10.15 Gleevec Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
Table 10.16 Gleevec Sales Forecast, Long Term: Base Scenario (USD Million)
Table 10.17 Gleevec Sales Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.18 Gleevec Sales Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.19 Tasigna Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Table 10.20 Tasigna Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
Table 10.21 Tasigna Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
Table 10.22 Tasigna Sales Forecast, Long Term: Base Scenario (USD Million)
Table 10.23 Tasigna Sales Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.24 Tasigna Sales Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.25 Sprycel Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Table 10.26 Sprycel Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
Table 10.27 Sprycel Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
Table 10.28 Sprycel Sales Forecast, Long Term: Base Scenario (USD Million)
Table 10.29 Sprycel Sales Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.30 Sprycel Sales Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.31 Bosutinib Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Table 10.32 Bosutinib Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
Table 10.33 Bosutinib Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
Table 10.34 Bosutinib Sales Forecast, Long Term: Base Scenario (USD Million)
Table 10.35 Bosutinib Sales Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.36 Bosutinib Sales Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.37 Iclusig Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Table 10.38 Iclusig Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)

Table 10.39 Iclusig Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
Table 10.40 Iclusig Sales Forecast, Long Term: Base Scenario (USD Million)
Table 10.41 Iclusig Sales Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.42 Iclusig Sales Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.43 Ibrutinib Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Table 10.44 Ibrutinib Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
Table 10.45 Ibrutinib Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
Table 10.46 Ibrutinib Sales Forecast, Long Term: Base Scenario (USD Million)
Table 10.47 Ibrutinib Sales Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.48 Ibrutinib Sales Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.49 Idealisib Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Table 10.50 Idealisib Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
Table 10.51 Idealisib Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
Table 10.52 Idealisib Sales Forecast, Long Term: Base Scenario (USD Million)
Table 10.53 Idealisib Sales Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.54 Idealisib Sales Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.55 Midostaurin Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Table 10.56 Midostaurin Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
Table 10.57 Midostaurin Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
Table 10.58 Midostaurin Sales Forecast, Long Term: Base Scenario (USD Million)
Table 10.59 Midostaurin Sales Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.60 Midostaurin Sales Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.61 ABT-199 Sales Forecast, Long Term: Base Scenario (USD Million)
Table 10.62 ABT-199 Sales Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.63 ABT-199 Sales Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.64 IPI-145 Sales Forecast, Long Term: Base Scenario (USD Million)
Table 10.65 IPI-145 Sales Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.66 IPI-145 Sales Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.67 Prevalence of Four Main Types of Leukemia in the US, 2013
Table 10.68 Incidence of Leukemia in the US, 2013 and 2014
Table 10.69 Oral Targeted Leukemia Drugs Market in the US, 2013 – Split by Drugs (USD Million)
Table 10.70 Incidence of Leukemia in Japan, 2012
Table 10.71 Leukemia Incidence: Major European Union Countries, 2012

The following companies and organizations have been mentioned in the report:

1. AbbVie
2. Agios Pharmaceuticals
3. Akinion Pharmaceuticals
4. Ambit Biosciences Corporation
5. Amgen
6. Apotex
7. ARIAD Pharmaceuticals
8. Arog Pharmaceuticals
9. Ascenta Therapeutics
10. Ascerta Pharma
11. Ash Stevens
12. Astellas Pharma
13. Asterias Biotherapeutics
14. AstraZeneca
15. Avillion Group
16. Bayer
17. BDR Pharma

18. BioMarin Pharmaceutical
19. Boehringer Ingelheim
20. Bristol-Myers Squibb
21. Calithera Biosciences
22. Catalent
23. Celltrion
24. Chroma Therapeutics
25. CytRx
26. Dana-Farber Cancer Institute
27. Esteve Quimica
28. Exelixis
29. Genentech
30. Genzyme
31. Gilead Sciences
32. GlaxoSmithKline
33. Haupt Pharma
34. Il-Yang Pharm. Co.
35. Incyte Corporation
36. Infinity Pharmaceuticals
37. Inovio

38. Janssen
39. Jiangsu HengRui Medicine Co.
40. Karyopharm Therapeutics
41. Kinex Pharmaceuticals
42. Lonza
43. Max Foundation
44. MEI Pharma
45. Merck
46. Millenium Pharmaceuticals
47. National Institute for Health and Care Excellence
48. Novartis
49. OncoEthix
50. Onconova Therapeutics, Inc.
51. Ono Pharmaceutical Co. Ltd
52. Otsuka Pharmaceutical
53. Pfizer
54. Pharmacyclics
55. Piramal Enterprises Limited
56. Plexxikon
57. Portola Pharmaceuticals
58. Roche
59. Samsung Biologics
60. Sandoz
61. Sanofi
62. Specialised Therapeutics Australia Pty Ltd (STA)
63. Tesaro
64. Teva Pharmaceuticals
65. TG Therapeutics
66. Tragara Pharmaceuticals, Inc.
67. University of Southampton
68. Wyeth